PGx Testing: Why Success Requires More Than Just Launching a Program

Pharmacogenomic (PGx) testing allows healthcare providers to make more informed, evidence-based decisions for their patients. To take advantage of this new clinical tool, we’ve recently seen several large

Recent Developments in Pharmacogenomics

For more than a decade, a robust body of evidence has progressively unveiled drug-genome interactions with important implications for health. Yet doctors and many health-care systems have been slow to implement

A Summary of the Latest CPIC 2019 Conference

The latest CPIC 2019 conference drew a diverse community of more than 200 attendees. The participants were mostly pharmacists (89) and laboratory professionals (102), confirming that successful implementations of

What You Need To Know About These 3 Newly Approved Drug-Genome Interactions

In 2018, 59 new medications earned FDA approval. Multigene pharmacogenomics (PGx) panels can safely prescribe three of these new drugs to prevent unnecessary toxicities and drug-genome interactions. A decade ago,

Exploring the Knowledge and Perspectives of US Payers on Preemptive Pharmacogenetic Testing

When it comes to wide-scale adoption of pharmacogenomics (PGx) testing, reimbursement has been one of the industry’s biggest roadblocks. This is especially true when it comes to the preemptive testing model. While